Big Pharma's dogfight to dominate the anti-obesity market | Health

Around the world, 100 companies have debuted weight-loss medications, which have become a multimillion-dollar business. Novo Nordisk’s Ozempic is currently the best-known, but it’s far from the only option

Related Keywords

United States ,Denmark ,Mexico ,Italy ,Belgium ,Germany ,Toronto ,Ontario ,Canada ,German ,Danish ,Steve Smith ,Javier Aledo ,Lars Fruergaard ,Daniel Drucker ,Zealand Pharma ,Stephen Freedman ,Novo Nordisk Ozempic ,Novo Nordisk ,Eli Lilly ,Bloomberg ,Barclays ,Capital Group ,International Financial Analysts ,European Union ,Goldman Sachs ,Amgen ,Organisation For Economic ,Cornell University ,Boehringer Ingelheim ,Astrazeneca ,Economic Co Operation ,Capital Markets ,Viking Therapeutics ,Holy Grail ,Spain Based International Financial ,Mount Sinai Hospital ,